D

Day One Biopharmaceuticals Inc
NASDAQ:DAWN

Watchlist Manager
Day One Biopharmaceuticals Inc
NASDAQ:DAWN
Watchlist
Price: 7.59 USD 1.74% Market Closed
Market Cap: 769.3m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

DAWN Price Targets Summary
Day One Biopharmaceuticals Inc

Wall Street analysts forecast DAWN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DAWN is 23.46 USD with a low forecast of 16.16 USD and a high forecast of 35.7 USD.

DAWN Lowest Forecast
Wall Street Target
16.16 USD
113% Upside
DAWN Average Forecast
Wall Street Target
23.46 USD
209% Upside
DAWN Highest Forecast
Wall Street Target
35.7 USD
370% Upside
Lowest
Price Target
16.16 USD
113% Upside
Average
Price Target
23.46 USD
209% Upside
Highest
Price Target
35.7 USD
370% Upside
Day One Biopharmaceuticals Inc Competitors:
Price Targets
TRDA
Entrada Therapeutics Inc
232% Upside
O
OSTX
OS Therapies Inc
474% Upside
MIRM
Mirum Pharmaceuticals Inc
10% Upside
D
DVYSR
Devyser Diagnostics AB
18% Upside
TRDA
Entrada Therapeutics Inc
232% Upside
O
OSTX
OS Therapies Inc
474% Upside
MIRM
Mirum Pharmaceuticals Inc
10% Upside
D
DVYSR
Devyser Diagnostics AB
18% Upside
301047
Sino Biological Inc
5% Upside
LGND
Ligand Pharmaceuticals Inc
7% Upside
ADCT
ADC Therapeutics SA
161% Upside

Revenue
Forecast

Revenue Estimate
Day One Biopharmaceuticals Inc

The compound annual growth rate of Day One Biopharmaceuticals Inc's revenue for the next 3 years is 36%.

N/A
Past Growth
36%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Day One Biopharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Day One Biopharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-30%
Average Miss
What are analyst estimates?

See Also

Summary
DAWN intrinsic value, competitors valuation, and company profile.
DCF Valuation
DAWN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
DAWN stock valuation using valuation multiples.
Wall Street Estimates
DAWN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
DAWN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is DAWN's stock price target?
Price Target
23.46 USD

According to Wall Street analysts, the average 1-year price target for DAWN is 23.46 USD with a low forecast of 16.16 USD and a high forecast of 35.7 USD.

What is Day One Biopharmaceuticals Inc's Revenue forecast?
Projected CAGR
36%

The compound annual growth rate of Day One Biopharmaceuticals Inc's revenue for the next 3 years is 36%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 278,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.